Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting [Yahoo! Finance]
Harrow, Inc. (HROW)
Last harrow, inc. earnings: 11/13 04:21 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Harrow, Inc. NASHVILLE, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that three scientific abstracts highlighting its commercial products VEVYE ® (cyclosporine ophthalmic solution) 0.1% and ILEVRO ® (nepafenac ophthalmic suspension) 0.3% have been accepted for presentation at the American Society of Cataract and Refractive Surgery (ASCRS) 2026 Annual Meeting, taking place April 10–13 at the Walter E. Washington Convention Center in Washington, D.C. The accepted research underscores Harrow's continued commitment to advancing evidence-based treatment options for ophthalmic diseases, including dry eye disease and post-cataract surgery complications. The abstracts will be presented in the following scientific sessions: Ocular Surface Disease Date: Saturday¸ April 11, 2026 Time: 8:00 AM – 9:30 AM VEVYE: Real-World Treatment Patterns and Clinical Outcomes with Cyc
Show less
Read more
Impact Snapshot
Event Time:
HROW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HROW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HROW alerts
High impacting Harrow, Inc. news events
Weekly update
A roundup of the hottest topics
HROW
News
- Harrow (HROW) had its "buy" rating reaffirmed by HC Wainwright. They now have a $70.00 price target on the stock.MarketBeat
- Harrow (HROW) was downgraded by Nomura to "neutral".MarketBeat
- Harrow (HROW) had its "buy" rating reaffirmed by BTIG Research. They now have a $63.00 price target on the stock.MarketBeat
- Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual MeetingGlobeNewswire
- Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market [Seeking Alpha]Seeking Alpha
HROW
Earnings
- 3/2/26 - Miss
HROW
Sec Filings
- 3/11/26 - Form SCHEDULE
- 3/10/26 - Form 8-K
- 3/5/26 - Form 4
- HROW's page on the SEC website